Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longmu + Gegen, also known as Longmu Gegen Decoction, is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the Chinese Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of herpes zoster and the management of postherpetic neuralgia (PHN). The formula is a combination of three core ingredients: Longgu (Fossil Bone), Muli (Oyster Shell), and Gegen (Puerariae Lobatae Radix). In the context of TCM, it is used to clear heat, resolve toxins, and calm the liver to alleviate severe neuropathic pain. Pharmacologically, the active isoflavones in Gegen, such as puerarin, are thought to provide analgesic and anti-inflammatory effects by inhibiting pro-inflammatory cytokines and potentially modulating P2X3 receptors and other ion channels involved in pain signaling. It is typically administered as an oral decoction in clinical hospital settings to reduce the duration of acute shingles pain and prevent the transition to chronic neuralgia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on longmu + gegen.